CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanchina, Michele, Pastore, Alessandro, Devlin, Sean, Famulare, Christopher, Stein, Eytan, Taylor, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704571/
https://www.ncbi.nlm.nih.gov/pubmed/31439003
http://dx.doi.org/10.1186/s13045-019-0771-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704571/
https://www.ncbi.nlm.nih.gov/pubmed/31439003
http://dx.doi.org/10.1186/s13045-019-0771-0

Ejemplares similares